The Riggs Difference: Where Understanding Leads to Recovery

Educational Events

Mild Neurocognitive Disorder: Evaluation and Decision-Making at the Gateway to Dementia

January 23, 2026 at 12:50 PM to 1:50 PM Eastern

FREE / 1.0 CE/CME Credit

Dr. Ellison reviews the clinical and biological bases for diagnosing and treating Mild Neurocognitive Disorder with a discussion of etiology, features, assessment, and treatment, both nonpharmacological and pharmacological.
2026 Grand Rounds Series
Speaker: James Ellison, MD, MPH
Mild Cognitive Impairment, officially known as Mild Neurocognitive Disorder, describes the acquired changes in mental functioning that constitute the border land between normal cognitive aging and Major Neurocognitive Disorder. As our aging population increases, we have been fortunate enough to have both new approaches to detection and new tools for treatment. In this presentation, Dr. Ellison will review the clinical and biological bases for diagnosing and treating Mild Neurocognitive Disorder with a discussion of etiology, features, assessment, and treatment, both nonpharmacological and pharmacological.